Nivolumab and Urelumab Active in Melanoma Regardless of PD-L1 Status
In conjunction with urelumab, nivolumab may be an effective treatment for patients with advanced or metastatic melanoma.
In conjunction with urelumab, nivolumab may be an effective treatment for patients with advanced or metastatic melanoma, according to a press release from Bristol-Myers Squibb.1
Results from a phase 1/2 study (ClinicalTrials.gov Identifier: NCT02534506) of urelumab and nivolumab for patients with a hematologic or solid cancer indicate that 18 of 46 patients with melanoma enrolled to this study had a confirmed objective response.
The response rates were similar regardless of PD-L1 status: 50% of PD-L1 positive and 47% of PD-L1 negative patients achieved a confirmed objective response.
There was no significant increase of treatment-related toxicity among patients who received urelumab plus nivolumab compared to that with nivolumab alone.
RELATED: Binimetinib + Encorafenib Improves PFS vs Vemurafenib in MelanomaSixty-three percent of patients in the melanoma cohort had a treatment-related adverse event, including fatigue, increased alanine transaminase (ALT), anemia, and increased aspartate transaminase (AST).
- Phase 1/2 data combining urelumab with Opdivo (nivolumab) in hematologic and solid tumors suggest increased antitumor effect in patients with melanoma. Bristol-Myers Squibb website. http://news.bms.com/press-release/bmy/phase-12-data-combining-urelumab-opdivo-nivolumab-hematologic-and-solid-tumors-sug. Updated November 12, 2016. Accessed November 17, 2016.